Aimei Health Technology Co., Ltd is a blank check company incorporated on April 27 2023 as a Cayman Islands exempted entity with the sole purpose of effecting a merger share exchange asset acquisition stock purchase reorganization or similar business combination with one or more businesses. The company completed its initial public offering on December 6 2023 selling 6 000 000 units at ten dollars per unit for gross proceeds of sixty million dollars. Simultaneously with the offering the underwriters exercised their over allotment option in full adding nine hundred thousand additional units and raising nine million dollars. A private placement with the sponsor added three hundred thirty two thousand units generating three million three hundred twenty thousand dollars. The combined proceeds of sixty nine million six hundred ninety thousand dollars were deposited into a trust account invested in short term United States government securities or money market funds with a maturity of 185 days or less. The company has until April 6 2025 to consummate an initial business combination subject to possible extensions funded by the sponsor. The sponsor Aimei Investment Ltd holds founder shares and private units and has agreed to provide additional monthly deposits to the trust to extend the deadline if needed. The company’s officers and directors have experience in financial oversight and healthcare operations in Asia.

Aimei Health Technology Co., Ltd does not engage in any manufacturing service or sales activities and therefore reports no operating revenue prior to a business combination. The funds held in the trust account generate interest income from investments in short term United States government securities or money market funds. This interest is accrued to the trust and will be distributed to shareholders upon redemption or liquidation if no business combination is completed. Should a business combination be consummated the company expects to derive revenue from the operations of the acquired business which may include product sales service fees licensing royalties or other commercial streams. Until such a transaction occurs the company’s financial statements reflect only interest earnings and administrative expenses related to being a publicly listed entity.

Aimei Health Technology Co., Ltd operates in the special purpose acquisition company arena where many sponsors seek to pair with innovative healthcare businesses. The company’s stated focus is on targets in the biopharmaceutical medical technology diagnostics and related healthcare sectors primarily in North America Europe and the Asia Pacific region. It competes with numerous other blank check companies private equity funds venture capital firms and strategic acquirers that also pursue healthcare related opportunities. The competitive landscape is characterized by limited capital availability for early stage companies and a high demand for public market access among healthcare innovators. Aimei Health Technology Co., Ltd differentiates itself through the experience of its management team in overseeing healthcare operations in Asia and its ability to offer target companies a route to U. S. capital markets that may be less costly and more certain than a traditional initial public offering. The company’s sponsorship structure provides a committed source of potential extension funding which can give it additional time to locate a suitable target compared with peers that lack such support.

Prior to completing a business combination the company does not serve customers or generate revenue from external parties. The individuals and entities that hold the company’s securities are its primary stakeholders consisting of the public shareholders who purchased units in the initial public offering and the private placement. These shareholders are entitled to a proportional share of the trust account proceeds upon redemption or liquidation and they may also receive shares in the post combined entity if a business combination is successful. The sponsor Aimei Investment Ltd holds a significant number of founder shares and private units and thus has a substantial economic interest in the outcome of any transaction. Should a business combination be completed the resulting entity will acquire a customer base that depends on the nature of the target business which may include hospitals clinics laboratories distributors or end users in the healthcare sector.